Abstract：Objective: To investigate the relationship and efficacy of the first-line chemotherapy combined with bevacizumab to K-ras gene status in advanced colorectal cancer (CRC). Methods: A retrospective analysis of 56 patients with CRC was conducted in this study, detected of K-ras gene status and treated with first-line chemotherapy combined with bevacizumab. The relationship between the mutation status of the K-ras gene and the response rate (RR), the progression free survival (PFS) and the total survival (OS) of the treatment was observed separately. Results: K-ras gene mutations were found in 58.2% of the patients with CRC.The K-ras gene mutation group transferred to the lung and liver more than the K-ras gene wild-type group, and the difference was statistically significant (P<0.05). There was no significant difference in RR rate and PFS between the two groups (P=0.61,0.83). The K-ras gene mutation group in OS was less than the wild type group, but the difference was not statistically significant (P=0.93). K-ras gene mutation was not a prognostic factor for PFS (P=0.86) and OS (P=0.17) in the Cox survival analysis model. Conclusion: The mutation status of the K-ras gene is not a prognostic factor of efficacy of the first-line chemotherapy combined with bevacizumab in CRC.
邢丽, 张勇, 李娟, 乔迁, 白莉. 晚期结直肠癌一线化疗联合贝伐珠单抗疗效与k-ras基因状态的关系[J]. 河北医学, 2018, 24(6): 886-889.
XING Li, ZHANG Yong, LI Juan, et al. The Relationship and Efficacy of the First-line Chemotherapy combined with Bevacizumab to K-ras Gene Status in Advanced Colorectal Cancer. HeBei Med, 2018, 24(6): 886-889.
[1] Bokemeyer C,Bondarenko I,Hartman JT,et al.Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer:the OPUS study[J].Ann Oncol,2011,22(7):1535~1546. [2] Garde Noguera J,Jantus-Lewintre E,Gil-Raga M,et al.Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab:A retrospective analysis[J].Mol Clin Oncol,2017,6(3):403~408. [3] García-Alfonso P, Grande E, Polo E.The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-ras status[J].Angiogenesis,2014,17(4):805~821. [4] 朱晓丽,蔡旭,张玲,等.中国结直肠癌患者中K-ras与BRAF基因突变特征及其临床病理相关性[J].中国病理学杂志,2012,41(9):584~589. [5] Seung Tae Kim,Kyong Hwa Park,Sang Won Shin, MD, PhD1Dose K-ras Mutation Status Affect on the Effect of VEGF Therapy in Metastatic Colon Cancer Patients[J].Cancer Res Treat,2014,46(1):48~54. [6] Vale CL,Tierney JF,Fisher D,et al.Does anti-EGFR therapy improve outcome in advanced colorectal cancer:a systematic review and meta-analysis[J].Cancer Treat Rev,2012, 38(6):618~625. [7] Basso M, Strippoli A, Orlandi A,et al.K-ras mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastaticcolorectal cancer patients[J].Br Cancer,2013,108(1):115~120. [8] Norguet E,Dahan L,Gaudart J,et al.Cetuximab after bevacizumab in metastatic colorectal cancer: is it the best sequence[J]Dig Liver Dis,2011,43(11):917~919. [9] Price TJ,Hardingham JE,Lee CK,et al.Impact of K-ras and BRAF gene mutation status on outcomes from the Phase III AGITG MAX Trial of capecitabine alone or in Combination with bevacizumab and mitomycin in advanced colorectal cancer[J].Clin Oncol,2011,29(19):2675~2682. [10] Brudvik KW,Kopetz SE,Li L,et al.Meta-analysis of K-ras mutations and survival after resection of colorectal liver metastases[J].Br Surg,2015,102(10):1175~1183.
2018, Vol. 24 
冀公网安备13080202000677号